Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma.
10.3760/cma.j.cn115330-20210608-00338
- Author:
Shen SHEN
1
;
Hong Fei LOU
1
;
Bing YAN
1
;
Yang WANG
1
;
Fei Fei CAO
2
;
Wei XIONG
2
;
Cheng Shuo WANG
3
;
Luo ZHANG
4
Author Information
1. Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, CAMS Innovation Fund for Medical Sciences, Beijing 100730, China Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China.
2. Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China.
3. Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China.
4. Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, CAMS Innovation Fund for Medical Sciences, Beijing 100730, China Department of Allergy, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Antibodies, Anti-Idiotypic;
Asthma/drug therapy*;
Chronic Disease;
Female;
Humans;
Male;
Middle Aged;
Nasal Polyps/drug therapy*;
Omalizumab/therapeutic use*;
Quality of Life;
Rhinitis/drug therapy*
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2021;56(10):1035-1041
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the short-term efficacy of anti-IgE monoclonal antibody (Omalizumab) in the treatment of recurrent chronic rhinosinusitis with nasal polyps (CRSwNP) complicated with asthma. Methods: Patients with recurrent CRSwNP and comorbid asthma in Beijing TongRen Hospital from May to December of 2020 were continuously recruited and received a 4-month therapy of stable background treatment plus Omalizumab. Results of visual analog scales (VAS) of nasal symptoms, sino-nasal outcome test-22 (SNOT 22) and nasal polyp scores were collected at baseline and post-treatment (1, 2, 3 and 4 months after treatment). Blood routine tests, total nasal resistances (TNR), minimum cross-sectional areas (MCA), total nasal cavity volumes (NCV), forced expiratory volumes in one second (FEV1)/forced vital capacity (FVC) and adverse events were collected at baseline and 4 months after treatment. All results were evaluated for short-term efficacy of Omalizumab. GraphPad Prism 8.2.1 was used for statistic analysis. Results: Ten patients were collected, including 3 males and 7 females, aged (41.13±12.64) years old (x¯±s). Compared to results at baseline, the VAS scores of nasal obstruction, rhinorrhea, hyposmia and headache after 4 months treatment were significantly decreased (1.80±1.48 vs 6.70±2.83, 2.40±1.27 vs 6.40±3.44, 2.70±2.91 vs 8.20±2.25, 0.60±1.08 vs 3.60±2.72, t value was 5.045, 4.243, 5.312, 3.402, respectively, all P<0.01). The scores of SNOT-22 (25.6±20 vs 61.3±33.32, t=4.127, P=0.002 6), nasal polyp scores (2.20±0.92 vs 4.60±0.84, t=9.000, P<0.01) and the count and percentage of eosinophils in peripheral blood were significantly decreased ((94.10±97.78)×109/L vs (360.00±210.80)×109/L, (32.90±27.06)% vs (64.40±20.73)%, t value was 3.678, 2.957, respectively, all P<0.05). NCV (0-5 cm and 0-7 cm) of patients were improved from baseline ((12.62±2.84) cm3 vs (10.40±2.09) cm3, (27.50±14.15) cm3 vs (16.81±6.40) cm3, t value was 2.371, 2.445, respectively, all P<0.05). Conclusions: The 4-month treatment of Omalizumab can significantly improve the nasal symptoms and quality of life of patients with recurrent CRSwNP complicated with asthma, shrink nasal polyps size and reduce the number of peripheral blood eosinophils. Omalizumab can be used as an alternative therapy for refractory CRSwNP patients in the future.
